Trevena, Inc. (TRVN)

0.4077 -0.0013 (-0.32%) 收市：04:00PM EDT

Trevena, Inc.

955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
https://www.trevena.com

版塊: Healthcare
行業: Biotechnology
全職員工: 23

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Carrie L. Bourdow	President, CEO & Chairman	1.08M	無	1963
Mr. Barry Shin	Executive VP, COO & CFO	722.79k	無	1972
Dr. Mark A. Demitrack M.D.	Senior VP & Chief Medical Officer	741.35k	無	1958
Dr. Howard A. Rockman M.D.	Scientific Founder, Consultant and Member of Scientific Advisory Board	無	無	無
Mr. Joel Solomon	VP, General Counsel, Company Secretary & Chief Compliance Officer	無	無	無
Mr. Michael Catalano	Vice President of Marketing	無	無	無
Mr. Robert T. Yoder	Senior VP, Chief Business Officer & Head of Commercial Operations	490.64k	無	1966
Ms. Patricia M. Drake	Senior VP & Chief Commercial Officer	無	無	1966

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

公司管治

截至 無 止，Trevena, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。